LLPC working group

Composition 

Chair

Prof. M.J. Kersten (AmsterdamUMC – AMC, Amsterdam)

Vice-Chair

Prof. M.C. Minnema (UMCU, Utrecht)

Secretary

Dr P. Mutsaers (ErasmusMC, Rotterdam)

Key objectives of working group

The key objectives of this working group are:

• To contribute actively to the implementation of so-called “first-in-man” phase I-II studies in malignant diseases of the blood, bone marrow and lymph nodes, including, but not limited to Non-Hodgkin's lymphoma (B and T cell), Hodgkin's lymphoma and chronic lymphocytic leukemia (CLL). Promising new drugs can then be incorporated in phase III studies, which are executed by the HOVON Lymphoma and CLL Working Groups. This creates the perspective to operate in the front line in HOVON with regard to the treatment of lymphomas and CLL with innovative therapies.
• By close collaboration, the turnaround time for deciding on studies, getting the protocol approved and enrolling the first patients is short.
• For the time being, it is expected that trials performed in the context of HOVON/LLPC will mainly be industry-sponsored trials. Ultimately, the goal is also to develop investigator-initiated studies. The working group will assess the relevance and feasibility of each study offered through one of its members or by industry. If it is decided to participate in the study on behalf of HOVON/LLPC, it will be determined by mutual agreement how many and which centers will participate, making sure there is regional spread. Non-participating centers are committed to refer patients to participating centers for study opportunities.

The Lunenburg Lymphoma Phase 1 / II Consortium (LLPC) was founded in 2009 by 5 departments of Hematology of Dutch (academic) hospitals. Currently, the participating hospitals are:

• AmsterdamUMC, locations AMC and VUMC, Amsterdam
• Erasmus Medical Center (Erasmus MC), Rotterdam
• University Medical Center Groningen (UMCG), Groningen
• Radboud University Medical Center (RadboudUMC), Nijmegen
• University Medical Center Utrecht (UMCU), Utrecht
• Leiden University Medical Center (LUMC), Leiden
• Maastricht University Medical Center (MUMC), Maastricht

Other centers can join the consortium if they are interested in and have the required facilities/dedicated study personnel to perform phase I/II studies.

Publication overview

• Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study
• KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma
• Tisagenlecleucel cellular kinetics, dose, and immunogenicity in relation to clinical factors in relapsed/refractory DLBCL
• Combining brentuximab vedotin with dexamethasone, high-dose cytarabine and cisplatin as salvage treatment in relapsed or refractory Hodgkin lymphoma: the phase II HOVON/LLPC Transplant BRaVE study
• A phase II study of venetoclax plus R-CHOP as first-line treatment for patients with diffuse large B-cell lymphoma
• Avadomide plus obinutuzumab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (CC-122-NHL-001): a multicentre, dose escalation and expansion phase 1 study
• Durable response with single-agent acalabrutinib in patients with relapsed or refractory mantle cell lymphoma.
• Phase I dose-escalation study of brentuximab-vedotin combined with dexamethasone, high-dose cytarabine and cisplatin, as salvage treatment in relapsed/refractory classical Hodgkin lymphoma: The HOVON/LLPC Transplant BRaVE study.
• Phase 2 Study of Daratumumab in Relapsed/Refractory Mantle-Cell Lymphoma, Diffuse Large B-Cell Lymphoma, and Follicular Lymphoma.
• European phase II study of mogamulizumab, an anti-CCR4 monoclonal antibody, in relapsed/refractory peripheral T-cell lymphoma.
• Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial. 
• Voxtalisib (XL765) in patients with relapsed or refractory non-Hodgkin lymphoma or chronic lymphocytic leukaemia: an open-label, phase 2 trial. 
• Final results of a phase 1b study of the safety and efficacy of the PI3Kδ inhibitor acalisib (GS-9820) in relapsed/refractory lymphoid malignancies.
• Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial.
• Nivolumab for Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Patients Ineligible for or Having Failed Autologous Transplantation: A Single-Arm, Phase II Study.
• Venetoclax plus R- or G-CHOP in non-Hodgkin lymphoma: results from the CAVALLI phase 1b trial.
• Final results of a phase 1b study of the safety and efficacy of the PI3Kδ inhibitor acalisib (GS-9820) in relapsed/refractory lymphoid malignancies.

Meetings & Minutes

Please note the section where meetings dates & minutes are shown are only accessible after log in.